|
1
|
Mason A, Malik S, McMillan M, McNeilly JD,
Bishop J, McGrogan P, Russell RK and Ahmed SF: A prospective
longitudinal study of growth and pubertal progress in adolescents
with inflammatory bowel disease. Horm Res Paediatr. 83:45–54.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sun PL and Zhang S: Correlations of
25-hydroxyvitamin D3 level in patients with ulcerative colitis with
inflammation level, immunity and disease activity. Eur Rev Med
Pharmacol Sci. 22:5635–5639. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lamas B, Richard ML, Leducq V, Pham HP,
Michel ML, Da Costa G, Bridonneau C, Jegou S, Hoffmann TW,
Natividad JM, et al: CARD9 impacts colitis by altering gut
microbiota metabolism of tryptophan into aryl hydrocarbon receptor
ligands. Nat Med. 22:598–605. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Jørgensen KK, Olsen IC, Goll GL, Lorentzen
M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien
TK, et al: NOR-SWITCH study group: Switching from originator
infliximab to biosimilar CT-P13 compared with maintained treatment
with originator infliximab (NOR-SWITCH): A 52-week, randomised,
double-blind, non-inferiority trial. Lancet. 389:2304–2316.
2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Baumgart DC and Sandborn WJ: Crohn's
disease. Lancet. 380:1590–1605. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ordás I, Eckmann L, Talamini M, Baumgart
DC and Sandborn WJ: Ulcerative colitis. Lancet. 380:1606–1619.
2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ananthakrishnan AN: Epidemiology and risk
factors for IBD. Nat Rev Gastroenterol Hepatol. 12:205–217.
2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mbachi C, Attar B, Oyenubi O, Yuchen W,
Efesomwan A, Paintsil I, Madhu M, Ajiboye O, Simons-Linares CR,
Trick WE and Kotwal V: Association between cannabis use and
complications related to ulcerative colitis inhospitalized
patients: A propensity matched retrospective cohortstudy. Medicine
(Baltimore). 98(e16551)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Jakubowska K, Pryczynicz A, Iwanowicz P,
Niewiński A, Maciorkowska E, Hapanowicz J, Jagodzińska D, Kemona A
and Guzińska-Ustymowicz K: Expressions of matrix metalloproteinases
(MMP-2, MMP-7, and MMP-9) and their inhibitors (TIMP-1, TIMP-2) in
inflammatory bowel diseases. Gastroenterol Res Pract.
2016(2456179)2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Khan S, Shukla S, Sinha S, Lakra AD, Bora
HK and Meeran SM: Centchroman suppresses breast cancer metastasis
by reversing epithelial-mesenchymal transition via downregulation
of HER2/ERK1/2/MMP-9 signaling. Int J Biochem Cell Biol. 58:1–16.
2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Giannopoulos G, Pavlakis K, Parasi A,
Kavatzas N, Tiniakos D, Karakosta A, Tzanakis N and Peros G: The
expression of matrix metalloproteinases-2 and -9 and their tissue
inhibitor 2 in pancreatic ductal and ampullary carcinoma and their
relation to angiogenesis and clinicopathological parameters.
Anticancer Res. 28B:B1875–B1881. 2008.PubMed/NCBI
|
|
12
|
Jakubowska K, Pryczynicz A, Januszewska J,
Sidorkiewicz I, Kemona A, Niewiński A, Lewczuk Ł, Kędra B and
Guzińska-Ustymowicz K: Expressions of matrix metalloproteinases 2,
7, and 9 in carcinogenesis of pancreatic ductal adenocarcinoma. Dis
Markers. 2016(9895721)2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kreijne JE, van der Giessen J, Verhaar AP,
Peppelenbosch MP, de Vries AC, van der Woude CJ and Fuhler GM:
Fecal matrix metalloproteinase-9 measurement for optimizing
detection of disease activity in inflammatory bowel disease. J Clin
Gastroenterol. 53:395–397. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Godefroy E, Gallois A, Idoyaga J, Merad M,
Tung N, Monu N, Saenger Y, Fu Y, Ravindran R, Pulendran B, et al:
Activation of toll-like receptor-2 by endogenous matrix
metalloproteinase-2 modulates dendritic-cell-mediated inflammatory
responses. Cell Rep. 9:1856–1870. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang J, Li Y and Qi Y: Effect of
glutamine-enriched nutritional support on intestinal mucosal
barrier function, MMP-2, MMP-9 and immune function in patients with
advanced gastric cancer during perioperative chemotherapy. Oncol
Lett. 14:3606–3610. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Langers AM, Verspaget HW, Hawinkels LJ,
Kubben FJ, van Duijn W, van der Reijden JJ, Hardwick JC, Hommes DW
and Sier CF: MMP-2 and MMP-9 in normal mucosa are independently
associated with outcome of colorectal cancer patients. Br J Cancer.
106:1495–1498. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Park MS, Martini WZ, Dubick MA, Salinas J,
Butenas S, Kheirabadi BS, Pusateri AE, Vos JA, Guymon CH, Wolf SE,
et al: Thromboelastography as a better indicator of hypercoagulable
state after injury than prothrombin time or activated partial
thromboplastin time. J Trauma. 67:266–276. 2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Nguyen NH, Fumery M, Dulai PS, Prokop LJ,
Sandborn WJ, Murad MH and Singh S: Comparative efficacy and
tolerability of pharmacological agents for management of mild to
moderate ulcerative colitis: A systematic review and network
meta-analyses. Lancet Gastroenterol Hepatol. 3:742–753.
2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Abraham C and Cho JH: Inflammatory bowel
disease. N Engl J Med. 361:2066–2078. 2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Silverberg MS, Satsangi J, Ahmad T, Arnott
ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C,
Geboes K, et al: Toward an integrated clinical, molecular and
serological classification of inflammatory bowel disease: Report of
a Working Party of the 2005 Montreal World Congress of
Gastroenterology. Can J Gastroenterol. 19 (Suppl A):A5–A36.
2005.PubMed/NCBI View Article : Google Scholar
|
|
21
|
17.Soop M, Nygren J, Thorell A and
Ljungqvist O: Stress-induced insulin resistance: Recent
developments. Curr Opin Clin Nutr Metab Care. 10:181–186.
2007.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Altshuler AE, Penn AH, Yang JA, Kim GR and
Schmid-Schönbein GW: Protease activity increases in plasma,
peritoneal fluid, and vital organs after hemorrhagic shock in rats.
PLoS One. 7(e32672)2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Brohi K, Singh J, Heron M and Coats T:
Acute traumatic coagulopathy. J Trauma. 54:1127–1130.
2003.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lu H, Liu H, Wang J, Shen J, Weng S, Han
L, Sun T, Qian L, Wu M, Zhu S, et al: The chemokine CXCL9
exacerbates chemotherapy-induced acute intestinal damage through
inhibition of mucosal restitution. J Cancer Res Clin Oncol.
141:983–992. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Gao Q, Meijer MJ, Schlüter UG, van
Hogezand RA, van der Zon JM, van den Berg M, van Duijn W, Lamers CB
and Verspaget HW: Infliximab treatment influences the serological
expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's
disease. Inflamm Bowel Dis. 13:693–702. 2007.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Li WL, Wu CH, Yang J, Tang M, Chen LJ and
Zhao SL: Local inflammation alters MMP-2 and MMP-9 gelatinase
expression associated with the severity of nifedipine-induced
gingival overgrowth: A rat model study. Inflammation. 38:1517–1528.
2015.PubMed/NCBI View Article : Google Scholar
|
